| Year |
Citation |
Score |
| 2024 |
Meyer CT, Smith BN, Wang J, Teuscher KB, Grieb BC, Howard GC, Silver AJ, Lorey SL, Stott GM, Moore WJ, Lee T, Savona MR, Weissmiller AM, Liu Q, Quaranta V, et al. Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies. Proceedings of the National Academy of Sciences of the United States of America. 121: e2408889121. PMID 39167600 DOI: 10.1073/pnas.2408889121 |
0.759 |
|
| 2024 |
Howard GC, Wang J, Rose KL, Jones C, Patel P, Tsui T, Florian AC, Vlach L, Lorey SL, Grieb BC, Smith BN, Slota MJ, Reynolds EM, Goswami S, Savona MR, et al. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition. Elife. 12. PMID 38682900 DOI: 10.7554/eLife.90683 |
0.587 |
|
| 2024 |
Silver AJ, Brown DJ, Olmstead SD, Watke JM, Gorska AE, Tanner L, Ramsey HE, Savona MR. Repair of leukemia-associated single nucleotide variants via interallelic gene conversion. Biorxiv : the Preprint Server For Biology. PMID 38659776 DOI: 10.1101/2024.04.16.587991 |
0.723 |
|
| 2024 |
Shannon ML, Heimlich JB, Olson S, Debevec A, Copeland Z, Kishtagari A, Vlasschaert C, Snider CA, Silver AJ, Brown D, Spaulding TP, Bhatta MR, Pugh K, Stockton SS, Ulloa J, ... ... Savona MR, et al. Clonal Hematopoiesis and Inflammation in the VasculaturE (CHIVE): a prospective, longitudinal cohort and biorepository. Blood Advances. PMID 38608257 DOI: 10.1182/bloodadvances.2023011510 |
0.7 |
|
| 2024 |
Mack T, Vlasschaert C, von Beck K, Silver AJ, Heimlich JB, Poisner H, Condon HR, Ulloa J, Sochacki AL, Spaulding TP, Kishtagari A, Bejan CA, Xu Y, Savona MR, Jones A, et al. Cost-effective and scalable clonal hematopoiesis assay provides insight into clonal dynamics. The Journal of Molecular Diagnostics : Jmd. PMID 38588769 DOI: 10.1016/j.jmoldx.2024.03.007 |
0.774 |
|
| 2024 |
Silver AJ, Vlasschaert C, Mack T, Sharber B, Xu Y, Bick AG, Pinson CW, Savona MR. Solid organ transplant recipients exhibit more TET2-mutant clonal hematopoiesis of indeterminate potential not driven by increased transplantation risk. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38551504 DOI: 10.1158/1078-0432.CCR-23-3840 |
0.677 |
|
| 2024 |
Heimlich JB, Bhat P, Parker A, Jenkins MT, Vlasschaert C, Ulloa J, Van Amburg J, Potts CR, Olson S, Silver AJ, Ahmad A, Sharber B, Brown D, Hu N, van Galen P, ... Savona MR, et al. Multiomic Profiling of Human Clonal Hematopoiesis Reveals Genotype and Cell-Specific Inflammatory Pathway Activation. Blood Advances. PMID 38507736 DOI: 10.1182/bloodadvances.2023011445 |
0.712 |
|
| 2024 |
Monteith AJ, Ramsey HE, Silver AJ, Brown D, Greenwood D, Smith BN, Wise AD, Liu J, Olmstead SD, Watke J, Arrate MP, Gorska AE, Fuller L, Locasale JW, Stubbs MC, ... ... Savona MR, et al. Lactate utilization enables metabolic escape to confer resistance to BET inhibition in acute myeloid leukemia. Cancer Research. PMID 38285895 DOI: 10.1158/0008-5472.CAN-23-0291 |
0.762 |
|
| 2024 |
Kishtagari A, Khan MAW, Li Y, Vlasschaert C, Marneni N, Silver AJ, von Beck K, Spaulding T, Stockton S, Snider C, Sochacki A, Dorand D, Mack TM, Ferrell PB, Xu Y, ... ... Savona MR, et al. Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk. Blood Cancer Journal. 14: 6. PMID 38225345 DOI: 10.1038/s41408-023-00974-9 |
0.78 |
|
| 2023 |
Ramsey HE, Gorska AE, Smith BN, Monteith AJ, Fuller L, Arrate MP, Savona MR. TLR3 agonism augments CD47 inhibition in acute myeloid leukemia. Haematologica. PMID 38152031 DOI: 10.3324/haematol.2023.283850 |
0.573 |
|
| 2023 |
Mack T, Vlasschaert C, von Beck K, Silver AJ, Heimlich JB, Poisner H, Condon HR, Ulloa J, Sochacki AL, Spaulding TP, Kishtagari A, Bejan CA, Xu Y, Savona MR, Jones A, et al. Cost-effective and scalable clonal hematopoiesis assay provides insight into clonal dynamics. Medrxiv : the Preprint Server For Health Sciences. PMID 37986782 DOI: 10.1101/2023.11.08.23298270 |
0.773 |
|
| 2023 |
Howard GC, Wang J, Rose KL, Patel P, Tsui T, Florian AC, Lorey SL, Grieb BC, Smith BN, Slota MJ, Reynolds EM, Goswami S, Savona MR, Lee T, Fesik SW, et al. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition. Biorxiv : the Preprint Server For Biology. PMID 37546802 DOI: 10.1101/2023.07.26.550648 |
0.58 |
|
| 2023 |
Moyo TK, Kishtagari A, Villaume M, McMahon B, Mohan SR, Stopczynski T, Chen SC, Fan R, Huo Y, Moon H, Tang Y, Bejan CA, Childress M, Anderson I, Rawling K, ... ... Savona MR, et al. PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in patients with Myelofibrosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37036505 DOI: 10.1158/1078-0432.CCR-22-3192 |
0.769 |
|
| 2023 |
Vlasschaert C, Mack T, Heimlich JB, Niroula A, Uddin MM, Weinstock JS, Sharber B, Silver AJ, Xu Y, Savona MR, Gibson CJ, Lanktree MB, Rauh MJ, Ebert BL, Natarajan P, et al. A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets. Blood. PMID 36652671 DOI: 10.1182/blood.2022018825 |
0.698 |
|
| 2022 |
Fischer MA, Song Y, Arrate MP, Gbyli R, Villaume MT, Smith BN, Childress MA, Stricker TP, Halene S, Savona MR. Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes. Haematologica. PMID 35979721 DOI: 10.3324/haematol.2022.280631 |
0.799 |
|
| 2022 |
Guess T, Potts CR, Bhat P, Cartailler JA, Brooks A, Holt C, Yenamandra A, Wheeler FC, Savona MR, Cartailler JP, Ferrell PB. Distinct patterns of clonal evolution drive myelodysplastic syndrome progression to secondary acute myeloid leukemia . Blood Cancer Discovery. PMID 35522837 DOI: 10.1158/2643-3230.BCD-21-0128 |
0.302 |
|
| 2022 |
Sochacki AL, Bejan CA, Zhao S, Patel A, Kishtagari A, Spaulding TP, Silver AJ, Stockton SS, Pugh K, Dorand RD, Bhatta MR, Strayer N, Zhang S, Snider CA, Stricker TP, ... ... Savona MR, et al. Patient-specific comorbidities as prognostic variables for survival in myelofibrosis. Blood Advances. PMID 35420683 DOI: 10.1182/bloodadvances.2021006318 |
0.767 |
|
| 2022 |
Jasra S, Giricz O, Zeig-Owens R, Pradhan K, Goldfarb DG, Barreto-Galvez A, Silver AJ, Chen J, Sahu S, Gordon-Mitchell S, Choudhary GS, Aluri S, Bhagat TD, Shastri A, Bejan CA, ... ... Savona MR, et al. High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. Nature Medicine. PMID 35256801 DOI: 10.1038/s41591-022-01708-3 |
0.705 |
|
| 2021 |
Ramsey HE, Stengel K, Pino JC, Johnston G, Childress M, Gorska AE, Arrate PM, Fuller L, Villaume M, Fischer MA, Ferrell PB, Roe CE, Zou J, Lubbock ALR, Stubbs M, ... ... Savona MR, et al. Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation. Targeted Oncology. PMID 34324169 DOI: 10.1007/s11523-021-00830-5 |
0.77 |
|
| 2021 |
Silver AJ, Bick AG, Savona MR. Publisher Correction: Germline risk of clonal haematopoiesis. Nature Reviews. Genetics. PMID 34140664 DOI: 10.1038/s41576-021-00384-2 |
0.664 |
|
| 2021 |
Silver AJ, Bick AG, Savona MR. Germline risk of clonal haematopoiesis. Nature Reviews. Genetics. PMID 33986496 DOI: 10.1038/s41576-021-00356-6 |
0.694 |
|
| 2021 |
Cojocari D, Smith BN, Purkal JJ, Arrate MP, Huska JD, Xiao Y, Gorska A, Hogdal LJ, Ramsey HE, Boghaert ER, Phillips DC, Savona MR. Pevonedistat and azacitidine upregulate NOXA () to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia. Haematologica. PMID 33853293 DOI: 10.3324/haematol.2020.272609 |
0.627 |
|
| 2021 |
Villaume MT, Arrate MP, Ramsey HE, Sunthankar KI, Jenkins MT, Moyo TK, Smith BN, Fischer MA, Childress MA, Gorska AE, Ferrell PB, Savona MR. The delta isoform of PI3K predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib. Experimental Hematology. PMID 33617893 DOI: 10.1016/j.exphem.2021.02.008 |
0.796 |
|
| 2020 |
Ramsey HE, Greenwood DL, Zhang S, Childress MA, Arrate MP, Gorska AE, Fuller LD, Zhao Y, Stengel KR, Fischer MA, Stubbs MC, Liu P, Boyd KL, Rathmell JC, Hiebert SW, ... Savona MR, et al. BET inhibition enhances the antileukemic activity of low-dose Venetoclax in acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33148670 DOI: 10.1158/1078-0432.CCR-20-1346 |
0.779 |
|
| 2020 |
Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, ... ... Savona MR, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine. PMID 32747829 DOI: 10.1038/S41591-020-1008-Z |
0.301 |
|
| 2020 |
Byrne M, Danielson N, Sengsayadeth S, Rasche A, Culos K, Gatwood K, Wyatt H, Chinratanalab W, Dholaria B, Ferrell PB, Fogo K, Goodman S, Jagasia M, Jayani R, Kassim A, ... ... Savona M, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. American Journal of Hematology. PMID 32390196 DOI: 10.1002/Ajh.25859 |
0.42 |
|
| 2020 |
Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Gurnani R, Saglio G. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. PMID 32265500 DOI: 10.1038/S41375-020-0805-1 |
0.363 |
|
| 2019 |
Wei AH, Strickland SA, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, et al. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801600. PMID 30892988 DOI: 10.1200/Jco.18.01600 |
0.345 |
|
| 2019 |
Smith BN, Savona M, Komrokji RS. Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). Clinical Lymphoma, Myeloma & Leukemia. 19: 1-8. PMID 30555034 DOI: 10.1016/J.Clml.2018.11.019 |
0.619 |
|
| 2019 |
Strickland SA, Podoltsev NA, Mohan SR, Zeidan AM, Childress MA, Ayers GD, Byrne MT, Gore SD, Stuart RK, Savona MR. The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid Leukemia Blood. 134: 180-180. DOI: 10.1182/Blood-2019-131520 |
0.768 |
|
| 2019 |
Pei S, Pollyea DA, Gustafson A, Minhajuddin M, Stevens BM, Ye H, Inguva A, Amaya ML, Krug A, Jones CL, Adane B, Winters A, Khan N, Ponder J, Schowinsky J, ... ... Savona MR, et al. Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy Blood. 134: 185-185. DOI: 10.1182/Blood-2019-131390 |
0.324 |
|
| 2019 |
Moyo TK, Watts JM, Skikne BS, Mendler JH, Klimek VM, Chen S, Fan R, Anderson IA, Sochacki A, Strickland SA, Byrne MT, Bradley TJ, Ayers GD, Mohan SR, Savona MR. Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition Blood. 134: 4236-4236. DOI: 10.1182/Blood-2019-130003 |
0.779 |
|
| 2019 |
Sochacki A, Zhao S, Bejan CA, Spaulding T, Stockton S, Silver A, Dorand D, Zhang S, Stricker T, Xu Y, Savona MR. JAK2V617F Clonal Hematopoiesis Stratifies By Peripheral Blood Counts. Blood. 134: 1203-1203. DOI: 10.1182/Blood-2019-129639 |
0.773 |
|
| 2019 |
Hilton CB, Meggendorfer M, Sekeres MA, Shreve J, Radakovich N, Rouphail Y, Walter W, Hutter S, Padron E, Savona MR, Gerds AT, Mukherjee S, Smith BN, Nagata Y, Hirsch CM, et al. Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms Blood. 134: 4238-4238. DOI: 10.1182/Blood-2019-126967 |
0.612 |
|
| 2019 |
Fischer MA, Arrate M, Childress MA, Smith BN, Song Y, Gbyli R, Stricker T, Halene S, Savona MR. Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition Blood. 134: 2982-2982. DOI: 10.1182/Blood-2019-126578 |
0.801 |
|
| 2019 |
Mason EF, Pozdnyakova O, Roshal M, Fathi AT, Stein EM, Shaver AC, Frattini MG, Wang H, Hua L, Mu J, Almon C, Cooper M, Stone RM, Hasserjian RP, Savona MR. Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy Blood. 134: 1442-1442. DOI: 10.1182/blood-2019-123845 |
0.301 |
|
| 2019 |
Smith BN, Cojocari D, Purkal JJ, Arrate M, Ramsey HE, Leverson JD, Boghaert E, Phillips DC, Savona MR. Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous Leukemia Blood. 134: 1380-1380. DOI: 10.1182/Blood-2019-123068 |
0.635 |
|
| 2019 |
Spaulding T, Strayer N, Sochacki A, Stockton S, Silver A, Dorand RD, Zhang S, Lin Y, Xu Y, Savona MR. Patient-Specific Risk Factors Independently Influence Survival in Myelodysplastic Syndromes in an Unbiased Review of EHR Records Blood. 134: 5440-5440. DOI: 10.1182/Blood-2019-122400 |
0.711 |
|
| 2019 |
Sochacki A, Bejan CA, Zhao S, Spaulding T, Stockton S, Silver A, Dorand D, Zhang S, Stricker T, Xu Y, Savona MR. Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis Blood. 134: 2959-2959. DOI: 10.1182/Blood-2019-121513 |
0.723 |
|
| 2019 |
Patel J, Cogle C, Foucar K, Grinblatt D, Komrokji R, Savona M, Scott B, Sekeres M, Steensma D, Flick D, Kiselev P, Louis C, Nifenecker M, Swern A, George T. Diagnostic Testing Patterns for Ring Sideroblasts (RS) in Patients with Newly Diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Connect® MDS/AML Disease Registry Clinical Lymphoma Myeloma and Leukemia. 19: S343-S344. DOI: 10.1016/J.Clml.2019.07.348 |
0.316 |
|
| 2018 |
Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, ... ... Savona MR, et al. Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). Blood. PMID 30242087 DOI: 10.1182/Blood-2018-05-848473 |
0.762 |
|
| 2018 |
Strickland SA, Shaver AC, Byrne M, Daber RD, Ferrell PB, Head DR, Mohan SR, Mosse CA, Moyo TK, Stricker TP, Vnencak-Jones C, Savona MR, Seegmiller AC. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. Leukemia Research. 65: 67-73. PMID 29310020 DOI: 10.1016/J.Leukres.2017.12.012 |
0.311 |
|
| 2018 |
Goldberg SL, Savona M, Mauro MJ. Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia. 18: 98-105. PMID 29274688 DOI: 10.1016/J.Clml.2017.11.006 |
0.38 |
|
| 2018 |
Stevens BM, Jones CL, Winters A, Dugan J, Abbott D, Savona MR, Fesik SW, Pollyea DA, Jordan CT. PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia Blood. 132: 909-909. DOI: 10.1182/Blood-2018-99-119806 |
0.336 |
|
| 2018 |
Hilton CB, Sekeres MA, Meggendorfer M, Walter W, Hutter S, Padron E, Savona MR, Gerds AT, Guan Y, Sallman DA, Mukherjee S, Patnaik MM, Smith B, Nagata Y, Adema V, et al. Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML) Blood. 132: 1813-1813. DOI: 10.1182/BLOOD-2018-99-115180 |
0.615 |
|
| 2018 |
Sochacki A, Bejan CA, Zhao S, Spaulding T, Stricker T, Xu Y, Savona MR. Next Generation Myelofibrosis Risk Analysis in the Electronic Health Record Blood. 132: 3038-3038. DOI: 10.1182/Blood-2018-99-113692 |
0.783 |
|
| 2018 |
Bejan CA, Sochacki A, Zhao S, Xu Y, Savona M. Abstract 5303: Identification of myelofibrosis from electronic health records with novel algorithms and JAKextractor Cancer Research. 78: 5303-5303. DOI: 10.1158/1538-7445.Am2018-5303 |
0.31 |
|
| 2017 |
Chen C, Siegel D, Gutierrez M, Jacoby M, Hofmeister CC, Gabrail N, Baz R, Mau-Sorensen M, Berdeja JG, Savona M, Savoie L, Trudel S, Areethamsirikul N, Unger TJ, Rashal T, et al. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom's macroglobulinemia. Blood. PMID 29203585 DOI: 10.1182/Blood-2017-08-797886 |
0.309 |
|
| 2017 |
Kuruvilla J, Savona M, Baz R, Mau-Sorensen M, Gabrail N, Garzon R, Stone R, Wang M, Savoie L, Martin P, Flinn I, Jacoby M, Unger TJ, Saint-Martin JR, Rashal T, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin's lymphoma. Blood. PMID 28468797 DOI: 10.1182/Blood-2016-11-750174 |
0.363 |
|
| 2017 |
Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, Savoie L, Mau-Sorensen M, Wagner-Johnston N, Yee K, Unger TJ, Saint-Martin JR, Carlson R, Rashal T, Kashyap T, et al. A phase I clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. PMID 28336527 DOI: 10.1182/Blood-2016-11-750158 |
0.393 |
|
| 2016 |
Moyo TK, Savona MR. Molecular Testing in Patients with Suspected Myelodysplastic Syndromes. Current Hematologic Malignancy Reports. 11: 441-448. PMID 27734261 DOI: 10.1007/s11899-016-0356-8 |
0.306 |
|
| 2016 |
Sochacki AL, Fischer MA, Savona MR. Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes. Oncotargets and Therapy. 9: 2273-86. PMID 27143923 DOI: 10.2147/OTT.S83868 |
0.77 |
|
| 2016 |
Carreau N, Tremblay D, Savona M, Kremyanskaya M, Mascarenhas J. Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. Blood Reviews. PMID 27106071 DOI: 10.1016/J.Blre.2016.04.003 |
0.329 |
|
| 2016 |
Sochacki AL, Fischer MA, Savona MR. Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes Oncotargets and Therapy. 9: 2273-2286. DOI: 10.2147/OTT.S83868 |
0.771 |
|
| 2016 |
Moyo TK, Sochacki A, Ayers GD, Byrne MT, Strickland SA, Mohan SR, Harrison J, Berry LD, Dudley CV, Severs R, Dugger L, Miskin HP, Cavers A, Sportelli P, Michaelis LC, ... ... Savona MR, et al. Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis Blood. 128: 1125-1125. DOI: 10.1182/Blood.V128.22.1125.1125 |
0.776 |
|
| 2016 |
Ye M, Liu M, Lu J, Lo Y, Favata M, Yang G, Diamond M, Dostalik V, Waeltz P, Fischer MA, He C, Wu L, Shan X, Chang H, Covington M, ... ... Savona M, et al. Abstract 4696: The LSD1 inhibitor INCB059872 is synergistic with ATRA in models of non-APL acute myelogenous leukemia Cancer Research. 76: 4696-4696. DOI: 10.1158/1538-7445.Am2016-4696 |
0.425 |
|
| 2015 |
Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, et al. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica. 100: 1117-30. PMID 26341525 DOI: 10.3324/Haematol.2014.114660 |
0.33 |
|
| 2015 |
Ferrell PB, Senapedis W, Cook A, Baloglu E, Landesman Y, Irish JM, Savona MR. Dissecting Signaling Network Responses to PAK4 Allosteric Modulators (PAMs) in Cell Subsets within Primary Human Acute Myeloid Leukemia Samples Blood. 126: 3686-3686. DOI: 10.1182/Blood.V126.23.3686.3686 |
0.316 |
|
| 2015 |
Steensma D, Abedi M, Bejar R, Cogle C, Foucar K, Garcia-Manero G, George T, Grinblatt D, Komrokji R, Maciejewski J, Pollyea D, Roboz G, Savona M, Scott B, Sekeres M, et al. 249 CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY Leukemia Research. 39: S124. DOI: 10.1016/S0145-2126(15)30250-2 |
0.316 |
|
| 2014 |
Steensma DP, Abedi M, Attar EC, Bejar R, Cogle CR, Garcia-Manero G, Grinblatt DL, Ma X, Maciejewski JP, Pollyea DA, Roboz GJ, Savona M, Scott BL, Sekeres MA, Thompson MA, et al. Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry. Journal of Clinical Oncology. 32: TPS7126-TPS7126. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps7126 |
0.361 |
|
| 2014 |
Gutierrez M, Goy A, Byrd JC, Flynn JM, Sorensen M, Brown P, Gabrail NY, Savona M, Flinn I, Baz RC, Shah BD, Stone RM, Jacobsen E, Kukreti V, Tiedemann RE, et al. A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology. 32: 8518-8518. DOI: 10.1200/Jco.2014.32.15_Suppl.8518 |
0.32 |
|
| 2014 |
Yee KWL, Savona M, Sorensen M, Brown P, Blum WG, DeAngelo DJ, Gutierrez M, Garzon R, Schuh AC, Gabrail NY, Wadleigh M, Lancet JE, Shah BD, Berdeja JG, Wagner-Johnston ND, et al. A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML). Journal of Clinical Oncology. 32: 7032-7032. DOI: 10.1200/Jco.2014.32.15_Suppl.7032 |
0.346 |
|
| 2014 |
Garcia-Manero G, Ritchie EK, Walsh K, Savona M, Kropf P, O'Connell C, Tibes R, Daver NG, Jabbour E, Lunin S, Rosenblat TL, Yee K, Stock W, Griffiths EA, Mace JR, et al. First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Blood. 124: 529-529. DOI: 10.1182/Blood.V124.21.529.529 |
0.37 |
|
| 2014 |
Crochiere M, Klebanov B, Baloglu E, Kalid O, Kashyap T, Senapedis W, del Alamo D, Rashal T, Tamir S, McCauley D, Carlson R, Savona M, Kauffman M, Shacham S, Landesman Y. In Vitro and in Vivo Quantification of Exportin-1 (XPO1) Occupancy By the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor in Multiple Myeloma, Acute Myeloid Leukemia, and Healthy PBMCs Blood. 124: 5196-5196. DOI: 10.1182/Blood.V124.21.5196.5196 |
0.351 |
|
| 2014 |
Stein EM, Garcia-Manero G, Rizzieri DA, Savona M, Tibes R, Altman JK, Jongen-Lavrencic M, Döhner H, Armstrong S, Pollock RM, Waters NJ, Legler M, Thomson B, Daigle S, McDonald A, et al. The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia Blood. 124: 387-387. DOI: 10.1182/Blood.V124.21.387.387 |
0.361 |
|
| 2014 |
Vij R, Savona M, Siegel DS, Kaufman JL, Badros A, Ghobrial IM, Paner A, Jagannath S, Jakubowiak A, Mikhael JR, Kapoor P, Neuman LL, Lee JR, Berdeja JG. Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study Blood. 124: 34-34. DOI: 10.1182/Blood.V124.21.34.34 |
0.306 |
|
| 2014 |
Senapedis W, George R, McCauley D, Ellis J, Crochiere M, Savona M, Shacham S, Landesman Y, Baloglu E. Novel Selective Orally Bioavailable Small Molecule PAK4 Allosteric Modulators (PAMs) Display Anti-Tumor Activity in Vitro and in Vivo in Hematological Malignancies Blood. 124: 2208-2208. DOI: 10.1182/Blood.V124.21.2208.2208 |
0.373 |
|
| 2013 |
Kuruvilla J, Gutierrez M, Shah BD, Gabrail NY, de Nully Brown P, Stone RM, Garzon R, Savona M, Siegel DS, Baz R, Mau-Sorensen M, Davids MS, Byrd JC, Shacham S, Rashal T, et al. Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Blood. 122: 90-90. DOI: 10.1182/Blood.V122.21.90.90 |
0.372 |
|
| 2013 |
Mascarenhas J, Talpaz M, Gupta V, Savona M, Coughlin P, Winton E, Hunter D, Mookerjee B, Leopold L, Clark J, O'Neill P, Ccrp, Hoffman R, Verstovsek S. An Open-Label, Phase II Study Of The JAK1 Inhibitor INCB039110 In Patients With Myelofibrosis Blood. 122: 663-663. DOI: 10.1182/Blood.V122.21.663.663 |
0.347 |
|
| 2013 |
Kantarjian HM, Jabbour E, Yee K, Kropf P, O'Connell C, Stock W, Tibes R, Rizzieri D, Walsh K, Griffiths EA, Roboz GJ, Savona M, Ervin T, Podoltsev NA, Pemmaraju N, et al. First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML) Blood. 122: 497-497. DOI: 10.1182/Blood.V122.21.497.497 |
0.364 |
|
| 2013 |
Mauro M, Radich J, Cortes JE, Dakhil S, Keir C, Yi S, Wadleigh M, Oehler VG, Ervin T, Goldberg S, Savona M. Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR4.5) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update Blood. 122: 4015-4015. DOI: 10.1182/Blood.V122.21.4015.4015 |
0.34 |
|
| 2013 |
Berdeja J, Savona M, Chu L, Essell J, Murphy P, Bauer T, Raefsky E, Boccia RV, Flinn I. Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment Of Patients (Pts) With Multiple Myeloma Who Are Not Candidates For High Dose Chemotherapy Blood. 122: 3193-3193. DOI: 10.1182/Blood.V122.21.3193.3193 |
0.341 |
|
| 2013 |
Ghobrial IM, Kaufman JL, Siegel DS, Vij R, Badros A, Neuman L, Wong H, Anderl J, Savona M. Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study Blood. 122: 3184-3184. DOI: 10.1182/Blood.V122.21.3184.3184 |
0.317 |
|
| 2013 |
Gutierrez M, Brown PdN, Gabrail N, Baz R, Reece DE, Savona M, Trudel S, Siegel DS, Mau-Sorensen M, Kuruvilla J, Byrd JC, Shacham S, Rashal T, Yau CY, Ccrp, et al. Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM) Blood. 122: 1942-1942. DOI: 10.1182/Blood.V122.21.1942.1942 |
0.375 |
|
| 2013 |
Berdeja J, Savona M, Mace JR, Hart L, Essell J, Owera R, Arrowsmith E, Flinn I. A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM) Blood. 122: 1937-1937. DOI: 10.1182/Blood.V122.21.1937.1937 |
0.339 |
|
| 2013 |
-Manero GG, Savona M, Gore SD, Cogle CR, Conkling P, Beach C, Hetzer J, Dong Q, Skikne BS. Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS) Blood. 122: 1554-1554. DOI: 10.1182/Blood.V122.21.1554.1554 |
0.316 |
|
| 2012 |
Vakkalanka S, Viswanadha S, Niecestro R, Sportelli P, Savona M. TGR-1202 Suppresses AML and ALL Cells Via Selective Inhibition of PI3Kδ Kinase. Blood. 120: 2610-2610. DOI: 10.1182/Blood.V120.21.2610.2610 |
0.398 |
|
| 2011 |
Carter CC, McNamara LA, Onafuwa-Nuga A, Shackleton M, Riddell J, Bixby D, Savona MR, Morrison SJ, Collins KL. HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host & Microbe. 9: 223-34. PMID 21402361 DOI: 10.1016/J.Chom.2011.02.005 |
0.618 |
|
| 2011 |
Larochelle A, Savona M, Wiggins M, Anderson S, Ichwan B, Keyvanfar K, Morrison SJ, Dunbar CE. Human and rhesus macaque hematopoietic stem cells cannot be purified based only on SLAM family markers. Blood. 117: 1550-4. PMID 21163926 DOI: 10.1182/Blood-2009-03-212803 |
0.492 |
|
| 2009 |
Larochelle A, Savona M, Wiggins M, Anderson S, Morrison SJ, Dunbar CE. Human and Rhesus Macaque Hematopoietic Stem Cells Are Not Enriched in the CD150+CD48- SLAM Population. Blood. 114: 3531-3531. DOI: 10.1182/Blood.V114.22.3531.3531 |
0.488 |
|
| 2008 |
Savona M, Talpaz M. Getting to the stem of chronic myeloid leukaemia. Nature Reviews. Cancer. 8: 341-50. PMID 18385684 DOI: 10.1038/Nrc2368 |
0.367 |
|
| 2006 |
Savona MR, Kiel MJ, Leavitt AD, Morrison SJ. SLAM-Family Expression on Human Mobilized Peripheral Blood Progenitors. Blood. 108: 1675-1675. DOI: 10.1182/Blood.V108.11.1675.1675 |
0.7 |
|
| Show low-probability matches. |